Padeliporfin potassium is under clinical development by Steba Biotech and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Padeliporfin potassium’s likelihood of approval (LoA) and phase transition for Transitional Cell Cancer (Urothelial Cell Cancer) took place on 19 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Padeliporfin potassium Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Padeliporfin potassium overview

Padeliporfin dipotassium (Tookad) is a vascular-acting photosensitizer consisting of a water-soluble, palladium-substituted bacteriochlorophyll derivative which acts as an antineoplastic agent. It is formulated as lyophilized powder for solution for intravenous route of administration. It is indicated for treatment of  treatment for other solid tumors. Photodynamic Therapy (PDT) is a non conventional light therapy for treatment of cancer. It uses photosensitive drugs, that are triggered by light from a specific wavelength usually red or infrared on the light spectrum chart. Vascular targeted photodynamic therapy (VTP) with padeliporfin allows tumor-site specific cytotoxicity while

It was also under development for cholangiocarcinoma, choroidal neovascularization, endobronchial cancer, renal cancer, prostate cancer and non-small cell lung cancer.

Steba Biotech overview

Steba Biotech is a biotechnology company that offer research on prostate cancer. It conducts research program in different indicators such as prostate cancer at different stages, oesophagus cancer, upper urinary tract cancer, breast cancer and pancreatic cancer. It offers research and development programs. Steba Biotech research comprises pre clinical, phase 1, phase II, and phase III stages. The company expands its clinical development programs to other indications in oncology in targeting solid tumours in various organs. It has operating offices in France, Israel, USA, Brazil and Switzerland. Steba Biotech is headquartered in Luxembourg City, Luxembourg.

Quick View Padeliporfin potassium LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Padeliporfin potassium
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
  • Ophthalmology
Key Developers
  • Sponsor Company: Steba Biotech
  • Originator: Steba Biotech
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.